Authors

Jackeline Alger, National Autonomous University of Honduras
Annelies Wilder-Smith, Nanyang Technological University
Yinghui Wei, School of Engineering, Computing and Mathematics
Thalia Velho Barreto De Araújo, Universidade Federal de Pernambuco
Maria Vankerkhove, World Health Organization
Marília Dalva Turchi, Universidade Federal de Goiás
Mauro Teixeira, Universidade Federal de Minas Gerais
Adriana Tami, University of Groningen
João Souza, Universidade de São Paulo
Patricia Sousa, Reference Center for Neurodevelopment
Antoni Soriano-Arandes, Autonomous University of Barcelona
Carmen Soria-Segarra, SOSECALI C. Ltda
Clemente N Sanchez
Kerstin Daniela Rosenberger, Heidelberg University
Ludovic Reveiz, Pan American Health Organization
Arnaldo Prata-Barbosa, Instituto D'or de Pesquisa e Ensino
Léo Pomar, Centre Hospitalier de l'Ouest Guyanais
Rosado LE Pelá
Freddy Perez, Pan American Health Organization
Saulo D. Passos, FMJ
Mauricio Nogueira, Faculdade de Medicina de São José do Rio Preto
Trevor P. Noel, St. George's University Grenada
da Silva A Moura
Maria Elisabeth Moreira, Fundação Oswaldo Cruz
Ivonne Morales, Heidelberg University
Montoya MC Miranda
Demócrito De Barros Miranda-Filho, Universidade de Pernambuco
Lauren Maxwell, Emory University
Calum N.L. Macpherson, St. George's University Grenada
Nicola Low, University of Bern
Zhiyi Lan
Angelle Desiree Labeaud
Marion Koopmans
Caron Kim
Esaú João
Thomas Jaenisch
Cristina Barroso Hofer
Paul Gustafson
Patrick Gérardin
Jucelia S. Ganz
Ana Carolina Fialho Dias
Vanessa Elias
Geraldo Duarte
Thomas Paul Alfons Debray
María Luisa Cafferata
Pierre Buekens
Nathalie Broutet
Elizabeth B. Brickley
Patrícia Brasil
Fátima Brant
Sarah Bethencourt
Andrea Benedetti
Vivian Lida Avelino-Silva
Ricardo Arraes De Alencar Ximenes
da Cunha A Alves
Jackeline Alger

ORCID

Abstract

IntroductionZika virus (ZIKV) infection during pregnancy is a known cause of microcephaly and other congenital and developmental anomalies. In the absence of a ZIKV vaccine or prophylactics, principal investigators (PIs) and international leaders in ZIKV research have formed the ZIKV Individual Participant Data (IPD) Consortium to identify, collect and synthesise IPD from longitudinal studies of pregnant women that measure ZIKV infection during pregnancy and fetal, infant or child outcomes.Methods and analysisWe will identify eligible studies through the ZIKV IPD Consortium membership and a systematic review and invite study PIs to participate in the IPD meta-analysis (IPD-MA). We will use the combined dataset to estimate the relative and absolute risk of congenital Zika syndrome (CZS), including microcephaly and late symptomatic congenital infections; identify and explore sources of heterogeneity in those estimates and develop and validate a risk prediction model to identify the pregnancies at the highest risk of CZS or adverse developmental outcomes. The variable accuracy of diagnostic assays and differences in exposure and outcome definitions means that included studies will have a higher level of systematic variability, a component of measurement error, than an IPD-MA of studies of an established pathogen. We will use expert testimony, existing internal and external diagnostic accuracy validation studies and laboratory external quality assessments to inform the distribution of measurement error in our models. We will apply both Bayesian and frequentist methods to directly account for these and other sources of uncertainty.Ethics and disseminationThe IPD-MA was deemed exempt from ethical review. We will convene a group of patient advocates to evaluate the ethical implications and utility of the risk stratification tool. Findings from these analyses will be shared via national and international conferences and through publication in open access, peer-reviewed journals.Trial registration numberPROSPERO International prospective register of systematic reviews (CRD42017068915).

DOI

10.1136/bmjopen-2018-026092

Publication Date

2019-01-01

Publication Title

BMJ Open

Volume

9

Issue

6

ISSN

2044-6055

Embargo Period

2020-06-06

First Page

26092

Last Page

26092

Share

COinS